Vaginal scrub-and-paint versus paint-only preparation in total laparoscopic hysterectomy: surgical site infection and postoperative spotting outcomes in a randomised controlled trial Authors: Siriporn Somjit, Irene Ruengkhachorn, Numpueng Inthaphoe, Sarisa Tapala, Raveewan Sangprasert, Supit Boonkarn, Chanon Neungton, Sompop Kuljarusnont Published: 2026 ABSTRACT BackgroundNo consensus exists regarding optimal vaginal preparation techniques for preventing surgical site infections (SSIs) in laparoscopic hysterectomy. This study aimed to compare SSI incidence between vaginal scrub-and-paint and paint-only preparation methods.MethodsAssessor-blinded randomised controlled trial in a tertiary care hospital in Thailand. Eligible patients scheduled to undergo total laparoscopic hysterectomy, without immunocompromised status, intraoperative injury to adjacent organs, or contraindication to chlorhexidine gluconate. Participants who provided informed consent were randomised to receive either vaginal scrub-and-paint preparation or paint-only preparation. Data on SSI risk factors, operative parameters, and postoperative outcomes were collected for 30 days post-surgery. Data are presented as numbers (percentages), or medians (interquartile ranges [IQRs]). Categorical and continuous variables were analysed using appropriate statistical tests, with P < 0.05 as the criterion for significance.ResultsAmong 370 participants, median age was 46.5 years (IQR 43.0–51.0), median operative time was 160 min (IQR 125.0–198.75), and median blood loss was 50 mL (IQR 21.25–100.0). Median hospital stay was 2 days (IQR 2.0–2.0). Twenty-nine patients (7.8%) had malignancy. No SSIs occurred in either group. Thirteen patients (7%) in the scrub-and-paint group experienced vaginal spotting.ConclusionsWithin the limitations of this prematurely discontinued trial and the absence of SSI events, both regimens appeared comparable regarding SSI, while scrub-and-paint was associated with more vaginal spotting.Clinical trial registrationThe study was registered with the Thai Clinical Trials Registry (reference 20230418002) on April 18, 2023. https://www.thaiclinicaltrials.org/show/TCTR20230418002.Supplementary InformationThe online version contains supplementary material available at 10.1186/s12905-026-04612-x. Introduction Among hospitalized surgical patients, the annual incidence of surgical site infections (SSIs) has been reported at 2%, although rates vary significantly across countries and regions [1, 2]. For example, the reported SSI rates are 0.9% in the United States, 2.6% in Italy, 2.8% in Australia, 2.1% in South Korea, and 6.1% in low- to middle-income countries. Notably, Southeast Asia reports particularly high rates, with an overall incidence of 7.8% between 2000 and 2012. These data underscore the importance of identifying region-specific risk factors for SSI [3]. Recognized patient-related risk factors for SSI include advanced age (> 60 years), history of radiation to the surgical area, prior soft tissue infections, poorly controlled diabetes mellitus, immunocompromised status, hypoalbuminaemia (serum albumin < 3.5 g/dL), hyperbilirubinaemia (total bilirubin > 1 mg/dL), obesity, alcoholism, and smoking. Procedure-related risk factors include prolonged operative time, significant blood loss, intraoperative hypothermia, extended hospital stays, and suboptimal sterile technique [3, 4]. Various methods have been recommended to reduce SSI risk, including optimisation of patient risk factors, appropriate antimicrobial prophylaxis, preoperative bathing, avoidance of unnecessary hair removal, meticulous surgical technique, maintenance of normovolaemia and normothermia, using wound-edge protectors, changing gloves, irrigating deep and subcutaneous tissues with saline, controlling operating room traffic and appropriate postoperative care [2, 3, 5–7]. In gynaecologic surgery, vaginal preparation is also commonly performed to reduce bacterial contamination during procedures that enter the vaginal canal. These range from doing nothing—based largely on clinical intuition—to more systematic chemical preparations applied both preoperatively (the day before surgery) and intraoperatively [8–12]. Povidone-iodine and chlorhexidine have been commonly recommended as antiseptic agents for vaginal preparation, with chlorhexidine demonstrating superior efficacy. Its effectiveness is not diminished by the presence of vaginal discharge, and it is not systemically absorbed [7–13]. The American College of Obstetricians and Gynecologists and the American Association of Gynecologic Laparoscopists recommend using 4% chlorhexidine for intraoperative skin and vaginal preparation in gynaecological procedures [7]. Neither organisation provides detailed guidance on the timing or specific application methods [7–14]. In particular, whether mechanical vaginal scrubbing adds clinically meaningful benefit beyond vaginal painting alone during total laparoscopic hysterectomy (TLH) remains unclear. At our institution, vaginal scrubbing followed by painting has been routinely used before TLH. However, this approach requires more time, materials, and personnel effort than painting alone and may cause minor mucosal irritation. The present study compared vaginal scrub-and-paint preparation with vaginal paint-only preparation before TLH, focusing on SSI within 30 days after surgery and postoperative vaginal spotting. Methods Study design and participants This assessor-blinded randomised controlled trial was conducted at the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand. The study was approved by the Siriraj Institutional Review Board (Si No. 224/2023), registered with the Thai Clinical Trials Registry (TCTR20230418002) on April 18, 2023, and initiated on April 24, 2023. All participants provided written informed consent; patients and the public were not involved in this study. The inclusion criterion was women aged 18 years or older who were scheduled to undergo TLH. The exclusion criteria were known allergy or contraindication to chlorhexidine gluconate, history of coagulopathy or current use of anticoagulant or antiplatelet medication, immune thrombocytopenic purpura, intraoperative injury to adjacent organs, and immunocompromised status including post-organ transplantation, systemic lupus erythematosus, rheumatoid arthritis requiring immunosuppressive therapy or corticosteroids, or HIV infection. The study was originally designed as a non-inferiority trial. A previous Singaporean study reported an SSI rate of 7.8%, indicating a non-infection rate of 92.2% (Pc = 0.922) in the control group. The test group was assumed to have the same non-infection rate as the control group (Pt = 0.922). A non-inferiority margin of 0.05 was defined, allowing up to a 5% absolute difference in non-infection rates between groups. With a Type I error (α) of 0.05 and a Type II error (β) of 0.20, and 80% power, the required sample size was 356 participants per group. Accounting for an anticipated 10% loss to follow-up, the total sample size was increased to 800 participants. A statistician generated the randomisation sequence. I.R. prepared the randomisation assignments in sequentially numbered, opaque, tamper-proof sealed envelopes. After intubation, participants were randomly assigned in a 1:1 ratio to the scrub-and-paint group or the paint-only group using a sealed-envelope method. Envelopes were opened only after anaesthesia induction, immediately before vaginal preparation by N.I. The operating-room team could not be blinded to the assigned preparation technique. Postoperative outcome assessors and nurses conducting follow-up telephone interviews were not involved in intraoperative allocation or vaginal preparation. Participants assigned to the scrub-and-paint group received vaginal scrubbing followed by vaginal painting. Vaginal scrubbing was performed with 4% chlorhexidine, and painting was done with 0.5% chlorhexidine in water—both antiseptic concentrations have been routinely used at our institution since 2020. Surgeries were performed according to clinical indications and surgeon preference. Preoperative antibiotics were administered within 1 h before the procedure using cefazolin 2 g, or 3 g for patients weighing > 120 kg. In patients with a penicillin allergy, clindamycin 900 mg was administered instead. For procedures lasting longer than 4 h, an additional intraoperative dose was administered. The use of postoperative antibiotics was determined by the treating clinician according to clinical judgement. Data collection In the postoperative ward, data about patients’ characteristics, diagnosis, prophylactic antibiotics, operation, estimated blood loss, operative time, and any complications were collected. After hospital discharge, data on surgical outcomes and complications were extracted from medical records up to 30 days postoperatively. Additionally, a blinded nurse assessor (S.S.) conducted follow-up telephone interviews on postoperative days 7 and 30 to assess patients’ recovery and provide guidance on postoperative care. Emergency visits or readmissions to our institution were reviewed. Events managed outside our institution may not have been completely captured unless reported by the patient during follow-up. Outcomes Diagnostic criteria for surgical site infection (SSI) included the presence of at least one of the following within 30 days postoperatively: (i) purulent discharge from the surgical site, (ii) wound dehiscence, (iii) microorganisms identified on culture, or (iv) a diagnosis of SSI by the treating physician. SSIs were classified into three categories—superficial incisional, deep incisional, and organ/space infections—according to the CDC guidelines [1]. Secondary outcomes included postoperative vaginal spotting, hospital stay, postoperative nausea, vomiting, ileus, epigastric pain, shoulder pain, time to ambulation, blood transfusion, hypothermia, adverse events related to vaginal preparation, and other postoperative complications. Postoperative vaginal spotting was defined as minimal vaginal bleeding or blood-stained vaginal discharge occurring after postoperative day 7 that did not require transfusion, readmission, pelvic examination under anaesthesia, surgical intervention, or other invasive management. Statistical approach IBM SPSS Statistics version 29.0 (IBM Corp, Armonk, NY, USA) was employed for all statistical analyses. The primary analysis was conducted according to the intention-to-treat principle. Because the study was originally designed as a non-inferiority trial, a per-protocol analysis was also performed for the primary outcome. Data are presented as numbers (percentages), means ± standard deviations, or medians and interquartile ranges (IQRs) according to data distribution. We analysed categorical variables using chi-square or Fisher’s exact tests, and continuous variables using Student’s t tests or Mann–Whitney U tests. Statistical significance was defined as p < 0.05. Absolute risk differences with 95% confidence intervals were calculated by Newcombe’s method for key outcomes. Results Study discontinuation and participant flow After 370 participants had been enrolled, no SSI events had been observed in either group. The estimated difference in infection rates, with a 95% confidence interval calculated using Newcombe’s method, ranged from − 2% to 2%, which remained within the predefined non-inferiority margin of 5%. Given the absence of SSI events, the probability of observing an overall SSI rate of 5% with continued enrollment to the planned sample size of 800 participants was considered low. Following internal discussion, the study was discontinued because no SSI events had occurred in either group (absolute risk difference, 0%) and postoperative vaginal spotting was observed more frequently in the scrub-and-paint group. Although the observed findings were consistent with the non-inferiority hypothesis, the trial did not reach the planned sample size and was therefore underpowered for the primary endpoint. Consequently, the primary outcome was interpreted descriptively rather than as definitive evidence of non-inferiority. This discontinuation was not based on a prespecified interim analysis or formal stopping rule. The early discontinuation and decision to proceed with data analysis were reported to the Siriraj Institutional Review Board according to institutional requirements. Figure 1 shows the flowchart of the study participants. Fig. 1Flowchart of study participants. The study was discontinued before reaching the planned sample size because no SSI events were observed in either group and postoperative vaginal spotting was more frequent in the scrub-and-paint group. No prespecified formal interim analysis or stopping rule was applied Flowchart of study participants. The study was discontinued before reaching the planned sample size because no SSI events were observed in either group and postoperative vaginal spotting was more frequent in the scrub-and-paint group. No prespecified formal interim analysis or stopping rule was applied Baseline characteristics and operative outcomes Baseline characteristics, surgical methods, and operative outcomes for the two study groups are presented in Table 1. Overall, the study included 370 participants. The median age was 46.5 years (IQR, 42.0–52.0), the median body mass index was 23.9 kg/m² (IQR, 20.8–27.1), and the median operative time was 155 min (IQR, 120–195). No participant reported tobacco use, and alcohol use was uncommon. A diagnosis of cancer was present in 29 patients (7.8%). Surgical procedures included total hysterectomy in 364 patients and radical hysterectomy in six patients. Surgeon expertise differed between groups, with a higher proportion of procedures performed by fellows in the paint-only group. Postoperative antibiotic use also differed between groups. The median hospital stay was 2.0 days (IQR, 2.0–2.0). Table 1Baseline characteristics, perioperative variables, and postoperative outcomes by study groupVariablesVaginal scrub-and-paint(n = 185)Vaginal paint-only(n = 185)P valueAge (years)48.8 ± 10.948.4 ± 8.40.697BMI (kg/m2)24.3 ± 5.124.9 ± 4.90.476Diseases Benign172 (93.0)169 (91.4)0.562 Malignant13 (7.0)16 (8.6)Tobacco use00NAAlcohol use1 (0.5)5 (2.7)0.154ASA classification0.130 I88 (47.6)74 (40.0) II89 (48.1)100 (54.1) III8 (4.3)11 (5.9) IV00Number of previous abdominal surgeries0.183 0101 (54.6)113 (61.1) 161 (33.0)56 (30.3) 222 (11.9)14 (7.6) 31 (0.5)2 (1.1)Comorbidities≠0.660 None88 (47.6)83 (44.9) Had97 (52.4)102 (55.1) Diabetes mellitus (n = 35)2114 Hypertension (n = 48)2523 Dyslipidaemia (n = 27)1215 Stroke (n = 2)11 Others (n = 87)3849Preoperative haemoglobin (g/dL)12.1 ± 1.612.2 ± 1.60.718Preoperative creatinine (mg/dL)0.71 ± 0.250.67 ± 0.190.171Surgeon expertise0.013 Staff180 (97.3)169 (91.4) Fellow5 (2.7)16 (8.7)Procedures0.410 TLH183 (98.9)181 (97.8) TLRHND2 (1.1)4 (2.2)Surgical time (min)161.3 ± 55.1172.2 ± 63.10.112Estimated blood loss (mL)71.5 ± 92.677.8 ± 96.70.525Blood transfusion01 (0.5)0.317Prophylactic antibiotics Penicillin177 (95.7)174 (94.1)0.480 Clindamycin8 (4.3)11 (5.9)Postoperative antibiotic use† Yes176 (95.1)148 (80.0)< 0.001 None9 (4.9)37 (20.0)Postoperative hypothermia3 (1.6)2 (1.1)1.000Postoperative nausea7 (3.8)9 (4.9)0.609Postoperative vomiting6 (3.2)7 (3.8)0.778Postoperative ileus3 (1.6)1 (0.5)0.623Postoperative epigastric pain34 (18.4)39 (21.1)0.514Postoperative shoulder pain33 (17.8)31 (16.8)0.783Time to first ambulation (hours)16.7 ± 2.916.3 ± 3.60.094Hospital stay (days)2.00 ± 0.751.86 ± 0.570.070Surgical site infection event‡00NAPostoperative vaginal spotting, n (%)13 (7.0)0< 0.001Data are presented as mean ± standard deviation or n (%), unless otherwise indicated. P values were calculated using Student’s t test, Mann–Whitney U test, chi-square test, or Fisher’s exact test, as appropriateAbbreviations: ASA American Society of Anesthesiologists physical status classification, BMI Body mass index, NA Not Applicable, TLH Total laparoscopic hysterectomy, TLRHND Total radical hysterectomy with pelvic node dissection≠ Comorbidities were not mutually exclusive† Postoperative antibiotic use was determined according to clinical judgement and institutional practice‡ P value was not calculated for SSI because no events occurred in either group Table 1Baseline characteristics, perioperative variables, and postoperative outcomes by study groupVariablesVaginal scrub-and-paint(n = 185)Vaginal paint-only(n = 185)P valueAge (years)48.8 ± 10.948.4 ± 8.40.697BMI (kg/m2)24.3 ± 5.124.9 ± 4.90.476Diseases Benign172 (93.0)169 (91.4)0.562 Malignant13 (7.0)16 (8.6)Tobacco use00NAAlcohol use1 (0.5)5 (2.7)0.154ASA classification0.130 I88 (47.6)74 (40.0) II89 (48.1)100 (54.1) III8 (4.3)11 (5.9) IV00Number of previous abdominal surgeries0.183 0101 (54.6)113 (61.1) 161 (33.0)56 (30.3) 222 (11.9)14 (7.6) 31 (0.5)2 (1.1)Comorbidities≠0.660 None88 (47.6)83 (44.9) Had97 (52.4)102 (55.1) Diabetes mellitus (n = 35)2114 Hypertension (n = 48)2523 Dyslipidaemia (n = 27)1215 Stroke (n = 2)11 Others (n = 87)3849Preoperative haemoglobin (g/dL)12.1 ± 1.612.2 ± 1.60.718Preoperative creatinine (mg/dL)0.71 ± 0.250.67 ± 0.190.171Surgeon expertise0.013 Staff180 (97.3)169 (91.4) Fellow5 (2.7)16 (8.7)Procedures0.410 TLH183 (98.9)181 (97.8) TLRHND2 (1.1)4 (2.2)Surgical time (min)161.3 ± 55.1172.2 ± 63.10.112Estimated blood loss (mL)71.5 ± 92.677.8 ± 96.70.525Blood transfusion01 (0.5)0.317Prophylactic antibiotics Penicillin177 (95.7)174 (94.1)0.480 Clindamycin8 (4.3)11 (5.9)Postoperative antibiotic use† Yes176 (95.1)148 (80.0)< 0.001 None9 (4.9)37 (20.0)Postoperative hypothermia3 (1.6)2 (1.1)1.000Postoperative nausea7 (3.8)9 (4.9)0.609Postoperative vomiting6 (3.2)7 (3.8)0.778Postoperative ileus3 (1.6)1 (0.5)0.623Postoperative epigastric pain34 (18.4)39 (21.1)0.514Postoperative shoulder pain33 (17.8)31 (16.8)0.783Time to first ambulation (hours)16.7 ± 2.916.3 ± 3.60.094Hospital stay (days)2.00 ± 0.751.86 ± 0.570.070Surgical site infection event‡00NAPostoperative vaginal spotting, n (%)13 (7.0)0< 0.001Data are presented as mean ± standard deviation or n (%), unless otherwise indicated. P values were calculated using Student’s t test, Mann–Whitney U test, chi-square test, or Fisher’s exact test, as appropriateAbbreviations: ASA American Society of Anesthesiologists physical status classification, BMI Body mass index, NA Not Applicable, TLH Total laparoscopic hysterectomy, TLRHND Total radical hysterectomy with pelvic node dissection≠ Comorbidities were not mutually exclusive† Postoperative antibiotic use was determined according to clinical judgement and institutional practice‡ P value was not calculated for SSI because no events occurred in either group Baseline characteristics, perioperative variables, and postoperative outcomes by study group Data are presented as mean ± standard deviation or n (%), unless otherwise indicated. P values were calculated using Student’s t test, Mann–Whitney U test, chi-square test, or Fisher’s exact test, as appropriate Abbreviations: ASA American Society of Anesthesiologists physical status classification, BMI Body mass index, NA Not Applicable, TLH Total laparoscopic hysterectomy, TLRHND Total radical hysterectomy with pelvic node dissection ≠ Comorbidities were not mutually exclusive † Postoperative antibiotic use was determined according to clinical judgement and institutional practice ‡ P value was not calculated for SSI because no events occurred in either group No adverse events were related to either vaginal preparation method. No SSIs occurred in either group. No SSI events occurred in either the intention-to-treat or per-protocol analyses. Therefore, the absolute risk difference for SSI was 0%; however, because the planned sample size was not reached and no primary endpoint events occurred, this finding should be interpreted descriptively and does not provide robust confirmation of non-inferiority. Postoperative vaginal spotting occurred in 13 of 185 patients (7.0%) in the scrub-and-paint group and in 0 of 185 patients (0%) in the paint-only group. The absolute risk difference for postoperative vaginal spotting was 7.0% with 95% confidence interval of 3.5% to 11.7%. These spotting events did not require transfusion, readmission, surgical intervention, or invasive management. Discussion In this prematurely discontinued randomised trial comparing vaginal scrub-and-paint versus paint-only preparation before TLH, no SSI events were observed in either group. These findings suggest that paint-only preparation may be adequate in similar low-risk TLH settings. However, interpretation should be cautious because the trial did not achieve the planned sample size and no primary endpoint events occurred. Accordingly, the SSI results should be regarded as descriptive safety outcomes rather than definitive evidence of equivalence or non-inferiority. The main observed difference between groups was postoperative vaginal spotting, which occurred only in the scrub-and-paint group, likely due to vulvovaginal abrasion from the mechanical action of scrubbing. This minor trauma did not appear to be sufficient to increase the risk of infection. However, spotting appeared clinically minor and self-limited, and no event required transfusion, readmission, surgical intervention, or invasive management. The absence of SSI events is consistent with previous evidence that SSI rates after minimally invasive hysterectomy are low, with reported rates ranging from 0% to 5.3% [15–18]. Total abdominal hysterectomy has been associated with higher SSI risk than TLH, with postoperative infection rates ranging from 4% to 21% and febrile morbidity reported in up to 30% of cases following total abdominal hysterectomy [9, 16, 18]. TLH appears to have infection rates closer to those observed after vaginal hysterectomy [16, 18]. Published data also indicate that the incidence of deep or vaginal infections was comparable across all surgical routes, ranging from 1% to 1.6% [7, 16]. The low event rate in the present cohort supports the general observation that SSI after TLH is uncommon, but it also substantially limits the ability to compare two low-risk vaginal preparation strategies. Bacterial contamination during surgery remains a primary cause of SSI. In laparoscopic hysterectomy, vaginal contamination may contribute importantly to postoperative infection. Previous studies have compared povidone-iodine and chlorhexidine in different gynaecologic surgical settings, with mixed findings regarding infectious morbidity and bacterial culture outcomes [11, 19–23]. For example, a retrospective study compared vaginal preparation with 10% povidone-iodine versus 4% chlorhexidine across different hysterectomy approaches: vaginal hysterectomy, total abdominal hysterectomy, and TLH. The study found statistically significant differences in infectious morbidity (4.3% vs. 3.0%, p = 0.01), urinary tract infections (1.7% vs. 1.1%, p = 0.03), and postoperative emergency department visits (9.7% vs. 7.9%, p = 0.01) between groups. However, there was no statistically significant difference in overall SSI rates (2.0% vs. 2.7%, p = 0.07) [11]. Similarly, a recent meta-analysis reported no significant difference in SSI rates following hysterectomy when comparing vaginal preparation with povidone-iodine and various concentrations of chlorhexidine. Both antiseptic agents were found to be safe for vaginal use [19]. Data on vaginal preparation for vaginal hysterectomy were reported from the Swedish National Registry for Gynecologic Surgery. In this study, 5,802 cases of vaginal hysterectomy were analysed and categorised into three groups based on the type of vaginal preparation: no cleansing, saline solution, and chlorhexidine solution. The incidence of vaginal cuff infection was 0.34%, 0.56%, and 0.57%, respectively, with no statistically significant differences observed among the groups [20]. Culligan et al. used a vaginal scrub before vaginal hysterectomy. They reported that 4% chlorhexidine was more effective than 10% povidone-iodine in reducing bacterial colony counts [21]. Vaginal preparation in TLH was investigated in a prospective study involving 1,377 patients. The protocol included a three-step vaginal cleansing process: scrubbing with 4% chlorhexidine five times, followed by vaginal painting with 10% povidone-iodine twice, and finally, instillation of 50 mL of antiseptic solution into the vaginal canal. The study reported a 1.8% SSI rate, all of which were classified as deep-space infections. Of the 24 patients who developed SSIs, five required re-operation for pelvic abscess management [22]. Marinone et al. performed a randomised controlled trial to compare 10% povidone-iodine with 2% and 4% chlorhexidine solutions. They performed a vaginal scrub three times before starting operations. Their investigation revealed higher rates of positive bacterial cultures after povidone-iodine, followed by 2% and 4% chlorhexidine in rates of 93.8%, 47.4%, and 20%, respectively. However, SSI rates were not reported [23]. Taken together, available evidence does not clearly define the optimal technique, concentration, timing, or frequency of vaginal antiseptic application before TLH. Our study contributes practical randomised data comparing two application techniques used in routine clinical practice, but it does not establish definitive comparative efficacy for SSI prevention. The current study has several strengths. It used a prospective randomised design, collected perioperative data systematically, and combined hospital-based record review with telephone follow-up at postoperative days 7 and 30. These features enhanced postoperative outcome ascertainment within the limits of the study setting. This study has several limitations. First, the trial discontinued before reaching the planned sample size. Although the study was originally designed as a non-inferiority trial, there was no prespecified interim analysis or formal stopping rule. Therefore, the study was underpowered for its primary endpoint, and the predefined non-inferiority margin could not be robustly assessed. Second, no SSI events occurred in either group. The absence of observed SSI events prevents meaningful comparative assessment of the primary endpoint and limits generalisability to settings with higher SSI rates. Third, microbiological cultures and bacterial colony count assessments were not performed, where clinical assessment might have missed a microscopic SSI diagnosis. Fourth, the study population included both benign and malignant indications and a small number of radical hysterectomy procedures. Some surgical variables that may influence SSI risk, including lymphadenectomy, uterine weight, colpotomy technique, vaginal manipulator use, specimen extraction method, and cuff closure technique, were not fully standardised or controlled for. Fifth, postoperative antibiotic use differed between groups. Although no SSI occurred in either arm, this imbalance may have influenced the observed SSI outcome and further limits causal interpretation of the comparison between preparation techniques. Finally, emergency visits or complications managed outside our institution may not have been completely captured unless reported by patients during follow-up. Future studies should include larger adequately powered populations, prespecified interim monitoring plans when applicable, clearer evaluation of microbiological endpoints, and comparisons of antiseptic types, concentrations, and timing for vaginal preparation. To maintain the effectiveness of patient care, international surveys should establish standardised education and training for medical personnel in disinfection techniques with regular testing. Conclusion Within the limitations of this prematurely discontinued trial and the absence of SSI events, the scrub-and-paint and paint-only regimens appeared comparable with respect to SSI prevention following laparoscopic hysterectomy, while the scrub-and-paint technique was associated with a higher frequency of vaginal spotting. Supplementary Information Supplementary Material 1. Supplementary Material 1.